SLC5A2 and congestive heart failure: State-of-the-art T2D therapeutics, namely glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, are used either alone or as an add-on to standard-of-care treatment, achieve desirable glycaemic control targets, confer non-glycaemic benefits of body weight loss and blood pressure reduction, and reduce the risk of atherosclerotic cardiovascular disease, congestive heart failure and chronic kidney disease3.